key: cord-0727440-ixpih091
authors: Valencia, Carlos Fernando; Lucero, Oscar David; Castro, Onofre Casas; Sanko, Andrey Alexandrovich; Olejua, Peter Alfonso
title: Comparison of ROX and HACOR scales to predict high-flow nasal cannula failure in patients with SARS-CoV-2 pneumonia
date: 2021-11-19
journal: Sci Rep
DOI: 10.1038/s41598-021-02078-5
sha: 7c99f15ba06eda3ac2bd7ec5e5416aa4841a81f1
doc_id: 727440
cord_uid: ixpih091

The pandemic of SARSCov2 infection has created a challenge in health services worldwide. Some scales have been applied to evaluate the risk of intubation, such as the ROX and HACOR. The objective of this study is to compare the predictive capacity of the HACOR scale and the ROX index and define the optimal cut-off points. Study of diagnostic tests based on a retrospective cohort. Composite outcome was the proportion of patients that needed endotracheal intubation (ETI) or died of COVID19 pneumonia. Discrimination capacity was compared by the area under the curve of each of the two scales and the optimal cut-off point was determined using the Liu method. 245 patients were included, of which 140 (57%) required ETI and 152 (62%) had the composite end result of high-flow nasal cannula (HFNC) failure. The discrimination capacity was similar for the two scales with an area under receiver operating characteristic curve of 0.71 and 0.72 for the HACOR scale for the ROX index, respectively. The optimal cut-off point for the ROX index was 5.6 (sensitivity 62% specificity 65%), while the optimal cut-off point for the HACOR scale was 5.5 (sensitivity 66% specificity 65%). The HACOR scale and the ROX index have a moderate predictive capacity to predict failures to the HFNC strategy. They can be used in conjunction with other clinical variables to define which patients may require invasive mechanical ventilation.

www.nature.com/scientificreports/ failure in patients with severe pneumonia. Roca et al. 6 found that a score of 4.9 after 2 h of HFNC therapy predicts failure to HFNC (AUROC of 0.74). In addition, studies have been done that validate its usefulness in patients with COVID19 pneumonia [12] [13] [14] . However, the main problem with the ROX scale lies in the delay in the initiation of IMV in people who require it. In 2017, Duan et al. 10 created a tool called HACOR, an acronym for heart rate, acidosis, state of consciousness, oxygenation, and respiratory rate (RR), to predict NIMV failure. In 2020, Carrilo et al. 12 validated this tool with 2711 patients, showing that the HACOR scale accurately predicted NIMV failure in the first hour. A cut-off value of 8 points at 1 h of HFNC beginning had an AUROC greater than 0.9 for predicting NIMV failure in patients with pneumonia and adult respiratory distress syndrome (ARDS). To our knowledge, the HACOR score has not been validated in patients with COVID19.

Although these scales have been validated in patients with severe pneumonia, we do not know if the HACOR scale is useful in patients with COVID19 and if its discrimination capacity is better than the ROX scale. The objective of this study is to compare the discrimination capacity between the HACOR and ROX scales to predict the risk of IMV in patients with severe SARSCOV2 pneumonia who are with HFNC strategy in the resuscitation unit of a hospital in Colombia.

Trial oversight. Study of diagnostic tests based on a retrospective cohort. We conducted the study in the emergency unit of a high complexity University Hospital in Bogota, Colombia. The study protocol was approved by the "Research and Institutional Ethics Committee of the faculty of medicine of the Pontificia Universidad Javeriana, and the Hospital Universitario San Ignacio". Since the study was based on data collection, patient consent was not required. This waiver is given in agreement with the Helsinki declaration and resolution number 008430 of 1993 issued by the Ministry of Health from the Republic of Colombia.

The first investigator was responsible for searching the hospital's database, while the second investigator ensured adherence to the protocol. Tests were conducted in accordance with principles of the Helsinki declaration. Authors assume responsibility for the integrity of the data and its analysis.

Total adult population identified with viral pneumonia by SARS CoV2 that required HFNC in the emergency department of the San Ignacio Hospital, between august and December of 2020 were eligible for enrollment. Data were taken from patients older than 18 years of age who had the diagnosis of SARS CoV2, confirmed by polymerase chain reaction (PCR). Patients with SARS CoV2 pneumonia who had required immediate ventilatory support with invasive mechanical ventilation and patients with severe or refractory agitation to sedation, massive bronchial aspiration, inability to manage bronchial secretions were excluded. Patients eligible for HFNC but with a signed will not to proceed to HFNC were also excluded.

Trial procedures. The decision to initiate a HFNC was made by the emergency physician or internist attending the patient, based on the following criteria: clinical presentation of respiratory failure (such as the use of accessory muscles, breathing rate greater than 20 respirations per minute, paradoxical abdominal movement, desaturation despite nasal cannula or venturi therapy), partial pressure of arterial oxygen (PaO2) less than < 60 mmHg or the PaO2/inspired fraction oxygen (FiO2) ratio < 300 with supplemental oxygen. In the emergency department of the San Ignacio Hospital, FiO2 ratio is currently calculated using the 3% formula [21% + (oxygen flow rate in L/min × 3)], which has been shown to have the highest accurate estimation of FiO2 in the literature 15 .

HFNC was managed by respiratory therapist professionals and patient's emergency physicians and internists, depending on the case. Masks, heated humidifiers, air-oxygen blenders, and cannulas (i.e., consumable materials) were owned by the Hospital. The device used as high-flow therapy was the Optiflow™ and the parameters at the beginning of the therapy were established according to the patient's last partial PaO2/FiO2 to achieve a SaO2 greater than 90%. Once respiratory failure improved, progressive decrease in the parameters of the HFNC were initiated. This was done when the patient had a breathing rate of fewer than 25 breaths per minute, without signs of muscle fatigue, had a SaO2 greater than 90%, and PaO2/FiO2 in ascent concerning that taken before the beginning of the HFNC. The inspired fraction of oxygen parameter was lowered initially and, according to the patient's tolerance, the flow parameter was subsequently lowered. All patients underwent gasometric monitoring before the onset of HFNC.

Every patient selected for our study was given HFNC therapy trial when considered necessary by the physician, there was no use of CPAP or other non invasive high flow oxygen therapy. The need to proceed to IMV was determined by the physician after a minimum of 2 h period and after a complete assessment of vital signs, arterial blood gas work and calculation of HACOR and ROX scales were performed. These procedures were done in a consistent basis independent of the specialist (emergency or internal medicine physician). If no improvement was noticed in each of the clinical (signs of muscle fatigue, SaO2 greater than 90%) and lab variables (PaO2/ FiO2 ascent), ETI was defined.

The definition of coinfection was that of the Centers for Disease Control and Prevention (US) 16 , which defines coinfection as one occurring concurrently with the initial infection. The diagnosis of coinfection was made in people with clinical and radiological criteria that were not compatible with COVID19 infection (for example, chest computed tomography that did not present a classic pattern of COVID19 infection, together with the microbiological finding by culture tests and polymerase chain reaction (PCR) taken from sputum or endotracheal aspirate within 48 h of admission. 

19 pneumonia who required HFNC therapy were described.

According to the recommendations of the Transparent reporting of a multivariable prediction model for Individual prognosis or diagnosis statement (TRIPOD) 17 , the minimum sample size was 100 events and 100 not events, so a minimum of 100 failures to the HFNC was sought. The baseline characteristics were compared between the treatment groups with the use of chi-square and Wilcoxon tests.

The discrimination capacity of the HACOR and ROX scales was evaluated using the area under the receiver operating characteristic curve (AUROC). The comparison of both scales was carried out by comparing the areas under the curve of the two scales. A secondary analysis of the ROX and HACOR scales was finally performed to predict failure of HFNC.

Finally, the Liu method was performed to identify the cut-off point with the best performance of the HACOR and ROX scales 18 .

Patient characteristics. A total of 245 patients were included in the study. Most of them were men (65%).

Mean (± SD) age of the patients was 62 (± 13) years. A total of 93 patients (38%) were 18-60 years of age and 152 (62%) were 60 years of age or older. 152 (62%) patients had the final composite outcome of HFNC failure (requirement of ETI or death by COVID19). Death associated with SARSCov2 infection occurred in 72 patients (29%). Table 1 shows key characteristics of the patients, stratified into two groups according to whether the patient had the final composite outcome. Interestingly, there were clinically significant imbalances in baseline characteristics with respect to prior history of hypertension, atrial fibrillation, and chronic kidney disease (CKD) between both groups.

In the HFNC failure group, the median age was 64 years (p = 0.04). Also, In the group with HFNC failure, there was a significantly higher number of people with atrial fibrillation, chronic kidney disease and hypertension. Of the clinical and paraclinical variables taken before the introduction of HFNC, the blood pressure of Co2 (PaCo2) (29.8 vs. 31.4, p = 0.014) and the Glasgow coma scale < 15 (p < 0.0001) were statistically significant between the groups that did not fail and those that did fail the HFNC (Table 1 ). There were statistically significant differences at 2 h after starting the HFNC strategy in the variables RR (25 vs. 22 breaths per minute p < 0.0001) ( Table 1) , pH (7.43 vs. 7.46, p = 0.004), SaO2 (92% vs. 95%, p < 0.0001), PaO2 (78.1 vs. 89.0, p < 0.0001), PaO2/Fio2 (103.6 vs. 133.2, p < 0.0001) ( Table 2 ). The 2-h ROX index was 6.6 and 5.6 for patients who did not fail and failed to HFNC, respectively (p < 0.0001). The HACOR score was 4.45 and 7.14 for patients who did not fail and failed to HFNC at 2 h, respectively (p < 0.0001). The mean time to failure of the HFNC was 1.4 days (± 3.8).

In univariate analysis ( Table 3 ) the variables that were associated with the worst outcome were HACOR score (OR 1.33, CI 1. In the univariate and multivariate analysis, the HACOR scale was the only one that maintained statistical significance. However, when the discrimination capacity of the HACOR and ROX scales was evaluated (Fig. 1) , it was found that the AUROC was similar for the two scales without significant differences (ROX AUROC 0.72 vs. HACOR AUROC 0.71). Those were just marginally better than AUROC of RR alone (0.69, 95% CI 0.63-0.76).

Finally, an estimate of the best cut-off point was made using the Liu method to predict the failure of the HNFC, finding that the value for HACOR scale was 5.5 with a sensitivity of 66% and a specificity of 65% (AUROC for the cut-off point of 0.66) while the cut-off point for ROX scale was 5.6 with a sensitivity of 62% and a specificity of 65% (AUROC for the cut-off point of 0.64).

In this study, we investigated the discrimination capacity of the ROX index and the HACOR scale to predict high-flow nasal cannula failure in patients with COVID19 pneumonia. Our data suggest that the discrimination capacity of the 2 scales is similar despite the scales evaluating different variables.

In our study we found that 140 (57%) patients required ETI and 152 (62%) had the final composite outcome of HFNC failure (requirement of ETI or death by COVID19). We believe that the differences in study populations may lead to variation in findings. Compared to the report by Roca et al. 6 , our sample analyzed had a higher median age (64 vs. 53 years). Also, a higher proportion of our patients on HFNC failure had CKD (13.8 vs. 4.5%). Secondly, our study found that patients with atrial fibrillation had a worse outcome. This variable was not evaluated by Roca et al. Furthermore, a later study did find that a heart rate greater than 90 beats per minute was associated with a higher risk of failure of HFNC 19 .

The discriminative capacity of both is similar (ROX AUROC 0.72 vs. HACOR AUROC 0.71). The discriminative capacity of the ROX index is similar to those observed in other studies [12] [13] [14] In our study, the best cut-off point for the ROX index to determine the success of HFNC was 5.6 (sensitivity 62% specificity 65%) and not 4.9, as previously established by Roca et al. 11 . On the other hand, the highest cut-off point of the HACOR scale to define the success of the HFNC was 5.5 (sensitivity 66%, specificity 65%), similar to that previously reported in the literature 21, 22 .

Interestingly, the HACOR scale was statistically significant in the multivariate analysis when comparing variables that are not included in the calculation of this scale, unlike the ROX index, which did not achieve statistical significance. We believe that this finding is due to the fact that the HACOR scale uses a greater number of variables that reached statistical significance such as the Glasgow scale, pH and PaO2/FiO2 2 h post HFNC, and that are not part of the ROX index. However, the discrimination capacity of the HACOR and ROX scales is similar. Given that the outcome we seek to avoid is mortality, we suggest using both scales to define the failure Table 1 . Characteristics of patients according to HFNC failure (final composite outcome including requirement of endotracheal intubation or death by COVID19). SD standard deviation, BMI body mass index, DM diabetes mellitus, CKD chronic kidney disease, HFNC high-flow nasal cannula, ACS acute coronary syndrome, COPD chronic obstructive pulmonary disease, CVA cerebrovascular accident, TIA transient ischemic attack, HIV human immunodeficiency virus, ETI endotracheal intubation. There were no significant differences (p < 0.05) between the study groups. a Before Introduction of HFNC. b 2 h post HFNC. † The bodymass index is the weight in kilograms divided by the square of the height in meters. www.nature.com/scientificreports/ of the HFNC, which would provide greater safety for the patient, although this would imply a closer monitoring of the person. Despite the fact that the RR in our study showed a slightly lower performance than the HACOR scale and the ROX index in predicting the failure of the HFNC, we consider that the use of parameters derived from the physical examination of the patient, such as the RR, can be a valuable tool to define the failure to the NIMV and of potential benefit in scenarios with limited resources. In this sense, scales such as WOB scale 23 have been developed and recommendations such as those of the Chinese Society of Anesthesiology 24 have been made in using parameters that are derived from simple clinical data such as the RR and the SpO2 to define HFNC failure. However none of them has been tested prospectively to predict HFNC outcome.

Although the predictive capacity of both scales is adequate, we believe that it was not so high that it could be used as the sole criterion to predict failure of the HFNC. Therefore, we consider necessary to add to these tools Table 2 . Basal and two hours arterial gases after initiation of the HFNC, distributed according to HFNC failure (final composite outcome including requirement of endotracheal intubation or death by COVID19). SD standard deviation, HFNC high-flow nasal cannula, SaO2 blood-oxygen saturation, PaO2 arterial partial pressure of oxygen, PaCO2 partial pressure of carbon dioxide, Fio2 fraction of inspired oxygen. There were no significant differences (p < 0.05) between the study groups. a Before HFNC. b 2 h post HFNC. Table 3 . Univariate and multivariate analysis of factors associated with the final composite outcome (requirement of endotracheal intubation or death by COVID19). There were no significant differences (p < 0.05) between the study groups. BMI body mass index, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, HFNC high-flow nasal cannula, SaO2 blood-oxygen saturation, PaO2 arterial partial pressure of oxygen, PaCO2 partial pressure of carbon dioxide, Fio2 fraction of inspired oxygen. a Before introduction of HFNC. b 2 h post HFNC. † The body-mass index is the weight in kilograms divided by the square of the height in meters. 27 . These aspects may represent a potential limitation in some of this study. Additionally, patient's history of HTA and CKD could potentially be useful to predict worse outcomes. These findings are consistent with The OpenSAFELY project 28 . Additionally, the Global Burden of Disease collaboration identified that worldwide, CKD is the most prevalent risk factor for severe COVID-19 29 . Although CKD patients are known to be at increased risk of death due to infectious diseases 30 , the factors contributing to their greater vulnerability for severe COVID-19 should be explored, as these may provide valuable insights into therapeutic approaches to the disease in this patient group. These variables could lead to the development of new models that allow a better prediction of the failure of the HFNC. New studies will be necessary to propose and evaluate these models.

Within the strengths of the study, this is the first study to compare the ability to predict cannula failure of the ROX and HACOR scales. Furthermore, it is one of the individual studies with the largest number of patients evaluated with HFNC and is the first to describe the discriminative capacity of the HACOR scale in patients with COVID19 pneumonia. Finally, we did not have data loss and we were able to count the outcomes of all the patients. Among the limitations of the study is the fact that the criteria to define the ETI requirement depended directly on the treating physician. However, the criteria for therapeutic failure to HFNC are clearly defined in our institution and these are part of a management protocol, which is why we believe that the decision for mechanical ventilation is similar among medical personnel.

The HACOR scale and the ROX index have a moderate predictive capacity to predict failures to the HFNC strategy. They can be used in conjunction with other clinical variables to define which patients may require invasive mechanical ventilation. www.nature.com/scientificreports/

Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis

Critical care utilization for the COVID-19 outbreak in Lombardy, Italy

High-flow, noninvasive ventilation and awake (nonintubation) proning in patients with COVID-2019 with respiratory failure

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A singlecentered, retrospective, observational study

Impact of ventilator model on mortality: A retrospective cross-sectional study in 147 mechanically ventilated patients with covid-19 Ards

Use of nasal high flow oxygen during acute respiratory failure

Knowledge translation tools to guide care of non-intubated patients with acute respiratory illness during the COVID-19 Pandemic

High flow nasal cannula useful for severe SARSs-CoV-2 pneumonia

High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure

Assessment of heart rate, acidosis, consciousness, oxygenation, and respiratory rate to predict noninvasive ventilation failure in hypoxemic patients

Predicting success of high-flow nasal cannula in pneumonia patients with hypoxemic respiratory failure: The utility of the ROX index

Validity of a clinical scale in predicting the failure of non-invasive ventilation in hypoxemic patients

High-flow nasal cannula therapy in COVID-19: Using the ROX index to predict success

Validity of rox index in prediction of risk of intubation in patients with covid-19 pneumonia

Reliability of methods to estimate the fraction of inspired oxygen in patients with acute respiratory failure breathing through non-rebreather reservoir bag oxygen mask

Antibiotic resistance threats in the United States. U.S. Department of Health and Human Services

Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement

Classification accuracy and cut point selection

Early prediction of high flow nasal cannula therapy outcomes using a modified ROX index incorporating heart rate

Prediction of mortality with the use of noninvasive ventilation for acute respiratory failure

Impact of HACOR score on noninvasive ventilation failure in non-COPD patients with acute-on-chronic respiratory failure

The utility of HACOR score in predicting failure of high-flow nasal oxygen in acute hypoxemic respiratory failure

Development of a work of breathing scale and monitoring need of intubation in COVID-19 pneumonia

Chinese Society of Anesthesiology Task Force on Airway Management: Expert recommendations for tracheal intubation in critically ill patients with novel coronavirus disease 2019

Viral respiratory infections: A cause of community-acquired pneumonia or a predisposing factor

Empiric antibacterial therapy and community-onset bacterial co-infection in patients hospitalized with COVID-19: A multi-hospital cohort study

Bacterial and fungal co-infections in COVID-19 patients hospitalized during the New York City Pandemic Surge

Factors associated with COVID-19-related death using OpenSAFELY

Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: A modelling study

Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: A nationwide analysis from Turkey

The authors declare no competing interests.

Correspondence and requests for materials should be addressed to O.D.L.Reprints and permissions information is available at www.nature.com/reprints.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.